

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/618,560
Filing Date	July 10, 2003
First Named Inventor	Keener et al.
Group Art Unit	1648
Examiner Name	J. Stucker
Attorney Docket Number	LIT-PI-529D1

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
JS		US-4,293,652	10/06/1981	Cohen	
		US- 4,350,626	09/21/1982	Masuhio et al.	
		US- 4,356,270	10/26/1982	Itakura	
		US- 4,416,988	11/22/1983	Rubin	
		US- 4,450,154	05/22/1984	Masuhio et al.	
		US- 4,458,066	07/03/1984	Canuthers et al.	
		US- 4,554,101	11/19/1985	Hopp	
		US- 4,683,195	07/28/1987	Mullis et al.	
		US- 4,683,202	07/28/1987	Mullis	
		US- 4,792,447	12/20/1988	Uhr et al.	
		US- 4,800,159	01/24/1989	Mullis et al.	
		US- 4,906,469	03/06/1990	Jansen et al.	
		US- 4,962,188	10/09/1990	Frankel	
		US- 4,965,188	10/23/1990	Mullis et al.	
		US- 5,135,736	08/04/1992	Anderson et al.	
		US- 5,165,923	11/24/1992	Thorpe et al.	
		US- 5,169,933	12/08/1992	Anderson et al.	
		US- 5,622,838	04/22/1997	Lord et al.	
		US- 5,981,493	11/09/1999	LaGrone	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 97/01636 A2	01/16/1997	Lentzen et al.		X
		JP 19850102188	11/17/1988	Takashi		X

Examiner Signature	JS	Date Considered	9/14/05
-----------------------	----	--------------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 7

**Complete if Known**

Application Number	10/618,560
Filing Date	July 10, 2003
First Named Inventor	Keener et al.
Group Art Unit	1648
Examiner Name	J. Stucker
Attorney Docket Number	LIT-PL 520D1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
J		ALAKHOV, V.Y., et al., Increasing Cytostatic Effects of Ricin A Chain and <i>Staphylococcus aureus</i> Enterotoxin A Through <i>In Vitro</i> Hydrophobization with Fatty Acid Residues, 12 Biotechnol. Appl. Biochem. 94-98 (1990)	
J		BEAUMELLE, B., et al., Ricin A Chain Can Transport Unfolded Dihydrofolate Reductase into the Cytosol, 272 J. Biol. Chem. 22097-22102 (1997)	
J		BROWN, E.L., et al., 68 Meth. Enzymol. 109 (1979) (phosphodiester method)	
J		BRYANT, M., et al., Myristoylation-dependent Replication and Assembly of Human Immunodeficiency Virus 1, 87 Proc. Nat'l Acad. Sci. USA 523-527 (1990)	
J		BULLER, R.M.L., et al., Poxvirus Pathogenesis, 55 Microbiol. Rev. 80-122 (1991)	
J		CHAMBERS, T.I., et al., Evidence that the N-terminal Domain of Nonstructural Protein NS3 from Yellow Fever Virus is a Serine Protease Responsible for Site-specific Cleavages in the Viral Polyprotein, 87 Proc. Nat'l Acad. Sci. USA 8898-8902 (1990)	
J		CHOU, K.C., A Vectorized Sequence-coupling Model for Predicting HIV Protease Cleavage Sites in Proteins, 268 J. Biol. Chem. 16938-16948 (1993)	
J		CHOU, K.C., Prediction of Human Immunodeficiency Virus Protease Cleavage Sites in Proteins, 233 Anal. Biochem. 1-14 (1996)	
J		CLAVERIE, J.M., et al., T-immunogenic Peptides Are Constituted of Rare Sequence Patterns. Use in the Identification of T Epitopes in the Human Immunodeficiency Virus Gag Protein, 18 J. Eur. Immunol. 1547-1553 (1988)	
J		CLOSS, O., et al., Stimulation of Human Lymphocytes by Galactose-specific <i>Abrus</i> and <i>Ricinus</i> Lectins, 115 J. Immunol. 1045-1048 (1975)	


Examiner  
SignatureDate  
Considered

9/14/05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 7

**Complete if Known**

Application Number	10/618,560
Filing Date	July 10, 2003
First Named Inventor	Keener et al.
Group Art Unit	1648
Examiner Name	J. Stucker
Attorney Docket Number	1 IT, PL 520D1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JS		FINBERG, R.W., et al., Selective elimination of HIV-1-infected Cells with an Interleukin-2 Receptor-specific Cytotoxin, 252 Science 1703-1705 (1991)	
		FRANZ, DAVID R. AND NANCY K. JAKK, MEDICAL ASPECTS OF CHEMICAL AND BIOLOGICAL WARFARE (Chpt. 32, Ricin Toxin) 631-642.	
JS		FRENOY, J.P., et al., Uptake of Injected <sup>125</sup> I-ricin by Rat Liver <i>In Vivo</i> , 284 Biochem. J. 249-257 (1992)	
JS		GATLIN, J., et al., Regulation of Intracellular Human Immunodeficiency Virus Type-1 Protease Activity, 244 Virology 87-96 (1998)	
		GenBank accession numbers X76644, X76720, X76721, X76722, X54873, X54872, X55667, X58937	
JS		GHIARA, J.B., et al., Crystal Structure of the Principal Neutralization Site of HIV-1, 264 Science 82-85 (1994)	
JS		HALLING, K.C., et al., Genomic Cloning and Characterization of a Ricin Gene from Ricinus communis, 13 Nucleic Acids Res. 8019-8033 (1985)	
		HOUGHTEN, 82 Proc. Natl Acad. Sci. USA 5131-35 (1985) (solid phase peptide synthesis)	
JS		HUNG, C.H., et al., Cloning and Expression of Three Abrin A-chains and Their Mutants Derived by Site-specific Mutagenesis in Escherichia coli, 219 Eur. J. Biochem. 83-87 (1994)	
JS		HUNG, C.H., et al., Primary Structure of Three Distinct Isoabrinins Determined by cDNA Sequencing: Conservation and Significance, 229 J. Mol. Biol. 263-267 (1993)	
JS		HUNKAPILLER et al., 310 Nature 105-111 (1984)	

Examiner Signature	JS	Date Considered	9/14/05
-----------------------	----	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 7

**Complete if Known**

Application Number	10/618,560
Filing Date	July 10, 2003
First Named Inventor	Keener et al.
Group Art Unit	1648
Examiner Name	J. Stucker
Attorney Docket Number	LIT-PL 520D1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>JS</i>		KABANOV, A.V., et al., Fatty Acylation of Proteins for Translocation Across Cell Membrane, 1 Biomed. Sci. 33-36 (1990)	
		<del>KATZ, R.A., et al., The Retroviral Enzymes, 63 Annu. Rev. Biochem. 133-173 (1994)</del>	
		KELLERMAN & FERENCI, 90 Methods in Enzymology 459-463 (1982)	
		KITAOKA, Y., Involvement of the Amino Acids Outside the Active-site Cleft in the Catalysis of Ricin A Chain, 257 Eur. J. Biochem. 255-262 (1998)	
		KORANT, B.D., Viral Proteases: An Emerging Therapeutic Target, 8 Crit. Rev. Biotechnol. 149-157 (1988)	
		KORNFELD, H., et al., Lymphocyte Activation by HIV-1 Envelope Glycoprotein, 335 Nature 6189 (1988)	
		KWONG, P.D., et al., Structure of an HIV gp120 Envelope Glycoprotein in Complex with the CD4 Receptor and a Neutralizing Human Antibody, 393 Nature 648-659 (1998)	
		KYTE, J., et al., A Simple Method for Displaying the Hydrophobic Character of a Protein, 157 J. Mol. Biol. 105-132 (1982)	
		LAMB, F.L., et al., Nucleotide Sequence of Cloned cDNA Coding for Prepraparin, 148 Eur. J. Biochem. 265-270 (1985)	
		LAMBERT, J.M., et al., An Immunotoxin Prepared with Blocked Ricin: a Natural Plant Toxin Adapted for Therapeutic Use, 51 Cancer Res. 6236-6242 (1991)	

Examiner Signature	<i>JS</i>	Date Considered	9/14/05
-----------------------	-----------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

7

**Complete if Known**

Application Number	10/618,560
Filing Date	July 10, 2003
First Named Inventor	Keener et al.
Group Art Unit	1648
Examiner Name	J. Stucker
Attorney Docket Number	11T-PL 529D1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LORD, J.M., et al., Ricin: Structure, Mode of Action, and Some Current Applications, 8 FASEB J. 201-208 (1994)	
		MATHE, G., The Kinetics of Cancer Cells and of HIV1: The Problems of Cell and Virus Rebounds and of Latency, 52 Biomed. Pharmacother. 413-420 (1998)	
		MIYOSHI, H., et al., Development of a Self-inactivating Lentivirus Vector, 72 J. Virol. 8150-8157 (1998)	
		NARANG, S.A., et al., 68 Meth. Enzymol. 90 (1979) (phosphotriester method)	
		PALLANCA, A., et al., Uncompetitive Inhibition by Adenine of the RNA-N-glycosidase Activity of Ribosome-inactivating Proteins, 1384 Biochim. Biophys. Acta 277-284 (1998)	
		PASTAN, I., et al., Recombinant Toxins for Cancer Treatment, 254 Science 1173-1177 (1991)	
		PATICK, A.R., et al., Protease Inhibitors as Antiviral Agents, 11 Clin. Microbiol. Rev. 614-627 (1998)	
		PERT, C.B., et al., Octapeptides Deduced from the Neuropeptide Receptor-like Pattern of Antigen T4 in Brain Potently Inhibit Human Immunodeficiency Virus Receptor Binding and T-cell Infectivity, 83 Proc. Nat'l Acad. Sci. USA 9254-9258 (1986)	
		PINCUS, S.H., et al., Anti-Human Immunodeficiency Virus Immunoconjugates, 32 Adv. Pharmacol. 205-247 (1995)	
		PINCUS, S.H., Therapeutic Potential of Anti-HIV Immunotoxins, 33 Antiviral Res. 1-9 (1996)	
		PUGACHEV, K.V., et al., Site-directed Mutagenesis of the Tick-borne Encephalitis Virus NS3 Gene Reveals the Putative Serine Protease Domain of the NS3 Protein, 328 FEBS Lett. 115-118 (1993)	
		RICHARDSON, P.T., et al., The Expression of Functional Ricin B-chain in <i>Saccharomyces cerevisiae</i> , 950 Biochim. Biophys. Acta 385-394 (1988)	

Examiner Signature		Date Considered	9/14/05
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

7

**Complete if Known**

Application Number	10/618,560
Filing Date	July 10, 2003
First Named Inventor	Keener et al.
Group Art Unit	1648
Examiner Name	J. Stucker
Attorney Docket Number	1 IT PL 529D1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ROBERTS, L. M., et al., Molecular Cloning of Ricin, 7 Targeted Diagn Ther 81-97 (1992)	
		ROBERTUS, J.D., et al., Structural Analysis of Ricin and Implications for Inhibitor Design, 34 Toxicon 1325-1334 (1996)	
		RUTENBER, E., et al., Structure of Ricin B-chain at 2.5 A Resolution, 10 Proteins 260-269 (1991)	
		SELA, B.A., et al., Lymphocyte Activation by Monovalent Fragments of Antibodies Reactive with Cell Surface Carbohydrates, 143 J. Exp. Med. 665-671 (1976)	
		SIMMONS, B.M., et al., Mannose Receptor-mediated Uptake of Ricin Toxin and Ricin A Chain by Macrophages, 261 J. Biol. Chem. 7912-7920 (1986)	
		SINHA, N.D., et al., 12 Nucl. Acids Res. 4539 (1984)	
		SINHA, N.D., et al., 15 Nucl. Acids Res. 397 (1987)	
		SINHA, N.D., et al., 16 Nucl. Acids Res. 319 (1988)	
		SINHA, N.D., et al., 24 Tetrahedron Lett. 5843 (1983)	
		Tözsér, J. et al., Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity, 272 J. Biol. Chem. 16807-16814 (1997)	
		TREGGAR, J.W., et al., The Lectin Gene Family of Ricinus communis: Cloning of a Functional Ricin Gene and Three Lectin Pseudogenes, 18 Plant Mol. Biol. 515-525 (1992)	

Examiner  
SignatureDate  
Considered

9/14/05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 7

**Complete if Known**

Application Number	10/618,560
Filing Date	July 10, 2003
First Named Inventor	Keener et al.
Group Art Unit	1648
Examiner Name	J. Stucker
Attorney Docket Number	LT PL 520D1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		VAN OIJEN, M.G.C.T., et al., Rationale for Use of Immunotoxins in the Treatment of HIV-infected Humans, 5 J. Drug Target 75-91 (1997)	
		VON DER HELM, K., Retroviral Proteases: Structure, Function and Inhibition from a Non-anticipated Viral Enzyme to the Target of a Most Promising HIV Therapy, 377 Biol. Chem. 765-774 (1996)	
		WANG, C.T., et al., Sequence Requirements for Incorporation of Human Immunodeficiency Virus Gag-2-galactosidase Fusion Proteins into Virus-like Particles, 59 J. Med. Virol. 180-188 (1999)	
		WESTBY, M., et al., Preparation and Characterization of Recombinant Procin Containing an Alternative Protease-sensitive Linker Sequence, 3 Bioconj. Chem. 375-381 (1992)	
		WOOD, K.A., et al., Preproabrin: Genomic Cloning, Characterisation and the Expression of the A-chain in Escherichia coli, 198 Eur. J. Biochem. 723-732 (1991)	
		WU, J.C., et al., Synthetic HIV-2 Protease Cleaves the OAG Precursor of HIV-1 with the Same Specificity as HIV-1 Protease, 277 Arch. Biochem. Biophys. 306-311 (1990)	
		WYATT, R., et al., The Antigenic Structure of the HIV gp120 Envelope Glycoprotein, 393 Nature 705-711 (1998)	
		WYATT, R., et al., The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens, 280 Science 1884-1888 (1998)	
		ZHANG, A., et al., A Disulfide-bound HIV-1 V3 Loop Sequence on the Surface of Human Rhinovirus 14 Induces Neutralizing Responses Against HIV-1, 380 Biol. Chem. 365-374 (1999)	
		ZUFFEREY, R., et al., Self-inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery, 72 J. Virol. 9873-9880 (1998)	

Examiner  
SignatureDate  
Considered

9/14/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.